Gear up for the most awaited metaverse-based global event!
Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain.
The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST)
Featuring renowned speakers from leading biopharma companies & organizations, the…
Shots:
The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023
In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…
Shots:
With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer
The global oncology drug market size in 2022 was valued at $185B and is forecasted to…
Shots:
With the noble responsibility of ensuring a healthy society on their shoulders, biopharma companies focused on Immunology are diligently working to develop treatments, vaccines, antibodies, and drugs
The global Immunology market was valued at $97.93B in 2021 and is anticipated to reach $184.21B by 2029 with a CAGR of 8.5 percent. In 2022, AbbVie…
Shots:
Tahi and Asud initiated the conversation with an overview of EPKINLYTM (epcoritamab) and its approval by the U.S. FDA to treat R/R DLBCL
They then spoke about the study design and results from the EPCORE NHL-1 P-I/II trial that served as the basis for the U.S. FDA approval of EPKINLY.
EPKINLY is being co-developed and co-commercialized by Genmab and AbbVie. Both companies are evaluating…
Are you ready to be part of a global movement to advance cancer research and treatment? This is your chance to connect with leading experts, healthcare professionals, and researchers from around the world.
Conference Series is delighted to welcome you to attend the 23rd World Congress on Cancer and Diagnostics scheduled in Toronto, Canada on…
In a landmark decision, FDA on June 20th, 2023 launched a new pilot program to mitigate the risks involved with certain Laboratory Developed Tests (LDTs) used to develop certain oncology products. It is an important initiative by FDA to address the safety standards associated with unregulated or poorly performing in vitro diagnostic tests. With an…
Shots:
Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine
He also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…
The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India.
Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…
Active Ingredient: Nivolumab
Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial
Dosage Form: Injection
Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1)
First Approval: US (22 Dec 2014), EU (19 Jun 2015)
Revenue Analysis of Opdivo
BMS’ Opdivo gives tough competition to other drugs in the…

